Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients

• Verfasst von: Lorenzen, Sylvie [VerfasserIn]
• Verfasst von: Blank, Susanne [VerfasserIn]
• Verfasst von: Ott, Katja [VerfasserIn]
• Titel: Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients
• Verf.angabe: Lorenzen Sylvie, Blank Susanne, Ott Katja
• Umfang: 21 S.
• Fussnoten: First online: 06 November 2012 ; Original paper is published in Ann Surg Oncol. 2012 Mar 7 [Epub ahead of print] ; Gesehen am 21.06.2018
• Titel Quelle: Enthalten in: Early gastrointestinal cancers
• Jahr Quelle: 2012
• Band/Heft Quelle: (2012), S. 269-289
• ISBN Quelle: 978-3-642-31629-6
• DOI: doi:10.1007/978-3-642-31629-6_18
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1576748464

Abstract

Introduction: Response to neoadjuvant chemotherapy (NAC) is an independent prognostic factor in locally advanced gastric cancer. However, no prospectively tested pretherapeutic parameters predicting response and/or survival in gastric cancer are available in clinical routine. Patients and methods: We evaluated the prognostic significance of various clinicopathologic parameters in 410 patients who were treated with NAC followed by gastrectomy. Clinical and histopathological response evaluation was performed using standardized criteria. A prognostic score was created on the basis of the variables identified in the multivariate analysis. Results: Multivariate analysis identified three pretherapeutic parameters as positive predictive factors for response and prognosis: tumor localization in the middle third of the stomach (p = 0.001), well differentiated tumors (p = 0.001) and intestinal tumor type according to Laurén’s classification (p = 0.03). From the obtained data a prognostic index was constructed, dividing the patients into three risk groups: low (n = 73), intermediate (n = 274), and poor (n = 63). The three groups had significantly different clinical (p = 0.007) and histopathological response rates (p = 0.001) and survival times, with a median survival time that was not reached in the low-risk group, 39.2 months in the intermediate-risk group and 20.5 months in the poor-risk group. The corresponding 5-year survival rates were 65.3, 41.2, and 21.2 % (p < 0.001), respectively. Conclusion: A simple scoring system based on three clinicopathologic parameters, accurately predicts response and prognosis in neoadjuvant treated gastric cancer. This system provides additional useful information that could be applied to select gastric cancer patients pretherapeutically for different treatment approaches. Prospective testing of the score in an independent patient cohort is warranted.